AI Article Synopsis
- A study evaluated the safety and effectiveness of an inactivated Japanese encephalitis vaccine (CVI-JE) in healthy Thai children aged around 14 months.
- Results showed that all participants developed strong antibody responses after vaccination, with high seroprotection rates both a year after the initial series and after a booster dose.
- Although some local and systemic reactions like fever and vomiting occurred, they were generally mild and self-limiting, indicating that CVI-JE is safe and immunogenic.
Article Abstract
Unlabelled: Inactivated mouse-brain-derived Japanese encephalitis vaccine has a worrisome safety profile and the live attenuated vaccine is unsuitable in immunodeficiency. This study aimed to evaluate the immunogenicity and safety of an inactivated chromatographically purified Vero-cell-derived JE vaccine (CVI-JE, Beijing P-3 strain) in children. 152 healthy Thai children, with an average (SD) age of 14.4 (3.8) months, received 3 doses of CVI-JE on days 0, 7-28, and one year. Homologous JE neutralizing antibody titers (NT) were measured. All subjects had seroprotection [geometric mean titer (GMT) 150] 28 days' post 2nd vaccination. The seroprotection rates at 1 year after primary series and and 1 month after the booster were 89.3% (GMT 49) and 100% (GMT 621), respectively. Local and systemic reactions-fever (17.6%), vomiting (8%), and poor appetite (5.3%)-were noted within 28 days' post-vaccination. All these symptoms were self-limited.
Conclusions: CVI-JE is safe, immunogenic, and provided high NT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893197 | PMC |
| http://dx.doi.org/10.1080/21645515.2017.1414763 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!